The phase III EORTC1325/KEYNOTE-054 trial evaluating Keytruda as adjuvant therapy in resected, high-risk stage III melanoma, met the key secondary endpoint of distant metastasis-free survival.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe